RE: Seen this?12 Oct 2020 18:22
Thanks Davey. Yes, you’re correct, it wasn’t meant as negative in the least. Simply that Foralumab has the potential to be colossal, and that AccuStem would pale into insignificance (albeit temporarily) off the back of success in Brazil.
Some are currently buying into Tiziana to realise spin off shares in AccuStem, which is fine, and if honest, is the reason I initially invested too. However, to put things in perspective 7 of the top 10 selling drugs last year world wide, were Monoclonal Antibodies, and as far as I can see, Foralumab looks like it’s going to be up there with the best of them. This means it will be vying for a share of the expected $150 Billion annual revenue generated by such drugs by 2024.
GL all.